RxDoctor Payments Data

Michael Ah You

Psychiatric/Mental Health · Payson, UTNPI 1396412698

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,345 and has fallen 52.2% since, to $642 in 2025. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,429in general payments, 2019–2025

Across 231 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$759
  • Otsuka America Pharmaceutical, Inc.$739
  • AbbVie$578
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$485
  • Neurocrine Biosciences, Inc.$473
  • Alkermes, Inc.$329
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,429 in reported general payments places this provider in the 90th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$93,658
Quetiapine Fumarate12$440
Trazodone Hcl21$205
Propranolol Hcl16$188
Eszopiclone11$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$473$93,65812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Payson

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →